Iovance Biotherapeutics, Inc. Common Stock (IOVA) Financials
Key financial figures for Iovance Biotherapeutics, Inc. Common Stock (Q2 2026).
Iovance Biotherapeutics, Inc. reported revenue of $99.3 million for Q2 FY2026, up 65.7% from the same period a year earlier. The company posted a net loss of $47.3 million, or -$0.11 per share. Operating margin came to -52.26%, against -189.78% a year earlier. Free cash flow for the period was -$66.3 million. Across the last 5 reported quarters, quarterly revenue has risen from $60.0 million in Q2 FY2025 to $99.3 million in Q2 FY2026. The figures above are as filed, and the full income statement, balance sheet and cash flow history for Iovance Biotherapeutics, Inc. are on the SentiSense financials page.
- Revenue
- $99M
- Net Income
- -$47M
- EPS
- $-0.11
- Total Assets
- $916M
- Operating Cash Flow
- -$61M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q2 FY2026 | $99M | -$47M | -$0.11 | -52.26% | -$66M |
| Q1 FY2026 | $71M | -$79M | -$0.19 | -113.46% | -$79M |
| Q4 FY2025 | $87M | -$72M | -$0.15 | -84.66% | -$62M |
| Q3 FY2025 | $67M | -$91M | -$0.25 | -140.69% | -$90M |
| Q2 FY2025 | $60M | -$112M | -$0.33 | -189.78% | -$75M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $264M | -$391M | -$1.09 | -153.08% | -$336M |
| FY2024 | $164M | -$372M | -$1.28 | -240.92% | -$364M |
| FY2023 | $1M | -$444M | -$1.89 | -38734.99% | -$384M |
Frequently asked questions
What was Iovance Biotherapeutics, Inc.'s revenue last quarter?
Iovance Biotherapeutics, Inc. reported revenue of $99.3 million for Q2 FY2026, up 65.7% from the same period a year earlier.
Is Iovance Biotherapeutics, Inc. profitable?
Not in its most recent reported period. Iovance Biotherapeutics, Inc. reported a net loss of $47.3 million for Q2 FY2026, a net margin of -47.64% on revenue.
How has Iovance Biotherapeutics, Inc.'s margin trended?
Operating margin was -52.26% in Q2 FY2026, compared with -189.78% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did Iovance Biotherapeutics, Inc. generate?
Iovance Biotherapeutics, Inc. generated free cash flow of -$66.3 million in Q2 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Iovance Biotherapeutics, Inc. Common Stock on SentiSense, with up to forty quarters and twenty fiscal years of history.